Nasdaq warns Enochian over missing annual report
The biotech company has fallen into disfavor with Nasdaq, which has imposed a 60-day deadline to get things in order.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
Embattled biotech company Enochian Biosciences has been on the receiving end of a wagging finger from the Nasdaq stock exchange due to a missing annual report, writes Danish business daily Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Angry investors sue Enochian Biosciences and owner
For subscribers
.jpg&w=384&q=75)
